Almac Clinical Technologies announced today that it has added 6,000 square feet of space at its Yardley, Pennsylvania USA headquarters to support the company's continued growth.
7th January 2009 Yardley, Pennsylvania. Almac Clinical Technologies announced today that it has added 6,000 square feet of space at its Yardley, Pennsylvania USA headquarters to support the company’s continued growth. The decision to expand the headquarters is part of the company’s strategy to provide an environment that spurs innovation, high quality project management, and customer service excellence.
President Jim Murphy comments on one of the reasons for the expansion: “Almac Clinical Technologies has experienced consistent growth the past few years, as several pharmaceutical and biotech companies have joined the ranks of our client base. The major overhaul of our technology platform from 2005-2007 has given us an edge over our competitors because our phone and web systems are truly integrated and our unique system architecture allows clients tremendous flexibility in support of their evolving technological standards and requirements. Our strong technology and unrivalled track record for service quality have been key drivers of Almac’s high client satisfaction ratings and ultimately our consistent growth.”
Karen Borda, Vice President of Production IT states that the expansion offers Almac Clinical Technologies the opportunity to build upon its strategy of creating synergistic teams that focus on high quality project management, technological innovation, and customer service excellence. “The addition of 6,000 square feet of new space offers Almac the opportunity to continue creating a work environment in which system developers, testers, project managers, R&D personnel, project support staff, and senior management can freely interact with each other and clients in an ideal setting. Our new space allows us to continue to foster a workplace in which face to face interaction between team members enhances training, mentoring, and information-sharing. Our focus is on delivering the highest quality systems and project management in the industry and this new space helps us achieve that goal.”
Almac completed the expansion and reorganization of its Yardley, PA offices in the week between Christmas and New Years, and will be offering its clients tours of the new expanded facilities during the next few months. This increase should accommodate growth until Almac Clinical Technologies moves into its new Headquarters based in Lansdale (PA) in 2010.
About Almac Clinical Technologies
Almac Clinical Technologies is a division of the Almac Group that specializes in interactive technology and service solutions to increase the quality and efficiency of the clinical trial process. Our solutions include Interactive Voice and Web Response Systems (IXRS™) for patient randomization, tracking and clinical supply management; iTrial EDC for electronic case report form data collection; electronic patient reported outcome data collection; and web drug reconciliation. Almac’s technologies have been deployed in over 1300 clinical trials, incorporating over 1.5 million patients in over 80 countries and more than 50 languages.
About Almac Group
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture. Almac provides services to over 600 companies including all the world leaders in the pharmaceutical and biotech sectors. The company employs over 2,000 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Construction of the company’s new $100m North American Headquarters started in July 08 and is expected to be completed 2010.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.